Springer Nature
Browse

Additional file 1: Table S1. of Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance

Download (55.94 kB)
journal contribution
posted on 2016-03-23, 05:00 authored by Jody Phelan, Francesc Coll, Ruth McNerney, David Ascher, Douglas Pires, Nick Furnham, Nele Coeck, Grant Hill-Cawthorne, Mridul Nair, Kim Mallard, Andrew Ramsay, Susana Campino, Martin Hibberd, Arnab Pain, Leen Rigouts, Taane Clark
The isolates according to geographic location and phenotypic drug resistance. CAR Central African Republic; DRC Democratic Republic of Congo, L1-L4 lineages 1 to 4, (first line drugs) RMP = rifampicin, INH = isoniazid, SM = streptomycin, EMB = ethambutol; (second line drugs) OFL = ofloxacin, KAN = kanamycin, CAP = capreomycin, Et = ethionamide, P = Para-aminosalisylic acid. Table S2. The isolate ENA accession numbers and MIC values. RMP rifampicin, INH isoniazid, SM streptomycin, EMB ethambutol. Table S3. Drug susceptibility profiles for rifampicin, isoniazid, streptomycin and ethambutol. R = resistance, S = sensitive; 13 different profiles were identified across 127 independent isolates; Multi-drug resistant in italics. Table S4. Combinations of mutations and their frequency (N) in drug resistance candidate genes. a) Rifampicin. b) Isoniazid. c) Streptomycin. d) Ethambutol. * single mutation, ** double mutations, *** triple mutations; SNP mutations in a single sample have been aggregated into a “rare” column. Table S5. Predicted effects of mutations. (DOCX 55 kb)

Funding

Biotechnology and Biological Sciences Research Council

History